

# Carlos Taxonera

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1996231/carlos-taxonera-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127 papers	3,188 citations	31 h-index	52 g-index
142 ext. papers	3,868 ext. citations	3.3 avg, IF	4.87 L-index

#	Paper	IF	Citations
127	Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1190-8	4.5	222
126	Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. <i>Gastroenterology</i> , <b>2013</b> , 145, 766-74.e1	13.3	180
125	Safety of thiopurines and anti-TNF- $\alpha$ drugs during pregnancy in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 433-40	0.7	157
124	2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 276-283	6.1	117
123	Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1662-9	4.5	113
122	Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 623-8	6.1	95
121	Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. <i>British Journal of Pharmacology</i> , <b>2004</b> , 141, 205-8	8.6	93
120	Long-Term Safety of In Utero Exposure to Anti-TNF- $\alpha$ Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 396-403	0.7	92
119	Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 340-8	6.1	76
118	Emerging treatments for complex perianal fistula in Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 4263-72	5.6	75
117	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 120-131	0.7	66
116	Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. <i>Journal of Crohns and Colitis</i> , <b>2012</b> , 6, 518-23	1.5	65
115	Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 2287-94	4.5	61
114	IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 1187-92	5.6	58
113	Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 37-43	1.9	57
112	Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 2003-8	0.7	56
111	Crohn's disease: a review of current treatment with a focus on biologics. <i>Drugs</i> , <b>2007</b> , 67, 2511-37	12.1	53

110	Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 839-851	6.1	53
109	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1394-1402	4.5	47
108	MDR1 gene: susceptibility in Spanish Crohn's disease and ulcerative colitis patients. <i>Inflammatory Bowel Diseases</i> , <b>2006</b> , 12, 33-7	4.5	47
107	Role of the PXR gene locus in inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 1484-1495	4.5	46
106	Novel association of the interleukin 2-interleukin 21 region with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1968-75	0.7	44
105	Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 1293-1301	1.5	43
104	Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15(-) Crohn's disease patients. <i>European Journal of Human Genetics</i> , <b>2009</b> , 17, 1304-8	5.3	42
103	Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility. <i>Immunogenetics</i> , <b>2007</b> , 59, 833-7	3.2	42
102	Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 575-9	2.4	38
101	High prevalence of viable Mycobacterium avium subspecies paratuberculosis in Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 4558-63	5.6	37
100	IL23R and IL12B polymorphisms in Spanish IBD patients: no evidence of interaction. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 1192-6	4.5	36
99	Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. <i>Human Immunology</i> , <b>2014</b> , 75, 71-5	2.3	33
98	Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 278-288	6.1	32
97	Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 481-490	4	31
96	Association of the organic cation transporter OCTN genes with Crohn's disease in the Spanish population. <i>European Journal of Human Genetics</i> , <b>2006</b> , 14, 222-6	5.3	31
95	Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-methyltransferase gene. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 615-20	5.6	31
94	Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 261-8	0.7	30
93	Genital fistulas in female Crohn's disease patients.: clinical characteristics and response to therapy. <i>Journal of Crohns and Colitis</i> , <b>2012</b> , 6, 276-80	1.5	27

92	Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. <i>European Journal of Internal Medicine</i> , <b>2011</b> , 22, 621-5	3.9	26
91	MYO9B polymorphisms in patients with inflammatory bowel disease. <i>Gut</i> , <b>2007</b> , 56, 1321-2	19.2	26
90	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 1492-1500	1.5	24
89	Health care costs of complex perianal fistula in Crohn's disease. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 3400-6	4	24
88	MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 585-90	4.5	24
87	Incidence, management, and course of cancer in patients with inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , <b>2015</b> , 9, 326-33	1.5	23
86	ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, 879-913	1.5	22
85	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 3075-84	4	21
84	Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. <i>Gastroenterología Y Hepatología</i> , <b>2008</b> , 31, 421-6	0.9	21
83	Increased risk of thiopurine-related adverse events in elderly patients with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 780-788	6.1	20
82	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 606-616	4.5	19
81	Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1697-704	4.5	19
80	Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 1086-91	2.2	19
79	Need for infliximab dose intensification in Crohn's disease and ulcerative colitis. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 9170-7	5.6	19
78	Eosinophilic colitis: Case series and literature review. <i>Pathology Research and Practice</i> , <b>2018</b> , 214, 100-104	4.4	18
77	Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. <i>Journal of Clinical Gastroenterology</i> , <b>2009</b> , 43, 950-6	3	18
76	GSTT1 and GSTM1 null genotypes may facilitate hepatitis C virus infection becoming chronic. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 1320-3	7	18
75	Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 419-428	6.1	18

74	Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 657-62	1.5	17
73	Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicron Study. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1840-1846	4.5	16
72	Using of magnetic resonance enterography in the management of Crohn's disease of the small intestine: first year of experience. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2012</b> , 104, 578-83	0.9	16
71	Analysis of the influence of two CD24 genetic variants in Crohn's disease and ulcerative colitis. <i>Human Immunology</i> , <b>2011</b> , 72, 969-72	2.3	16
70	Effect of BSN-MST1 locus on inflammatory bowel disease and multiple sclerosis susceptibility. <i>Genes and Immunity</i> , <b>2009</b> , 10, 631-5	4.4	16
69	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 846-854	4	15
68	Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	15
67	Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1862-1870	4.5	14
66	Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 318207	4.3	14
65	Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 792-800	1.5	13
64	A computer-assisted morphometric quantitative analysis of iron overload in liver biopsies. A comparison with histological and biochemical methods. <i>Pathology Research and Practice</i> , <b>2005</b> , 201, 673-74	3.4	13
63	Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, 35-42	1.5	13
62	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 1270-1279	1.5	12
61	Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 731-737	4	11
60	How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 733-7	3.3	11
59	CD209 in inflammatory bowel disease: a case-control study in the Spanish population. <i>BMC Medical Genetics</i> , <b>2007</b> , 8, 75	2.1	11
58	Epistatic interaction between FCRL3 and MHC in Spanish patients with IBD. <i>Tissue Antigens</i> , <b>2007</b> , 69, 313-7		11
57	Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 864-869	4.5	11

56	Comparison of sucralfate and ranitidine in the treatment of duodenal ulcers. <i>American Journal of Medicine</i> , <b>1991</b> , 91, 64S-67S	2.4	10
55	Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 2080-2087	4	9
54	Effectiveness of anti-TNF drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF agent. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 613-9	3.3	9
53	Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels. <i>Therapeutic Advances in Gastroenterology</i> , <b>2018</b> , 11, 1756284818783613	4.7	9
52	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 480-489	1.5	9
51	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , <b>2016</b> , 122, 33-41	6	9
50	Study of chromosomal region 5p13.1 in Crohn's disease, ulcerative colitis, and rheumatoid arthritis. <i>Human Immunology</i> , <b>2010</b> , 71, 826-8	2.3	8
49	What Is the Incidence of COVID-19 in Patients With IBD in Western Countries?. <i>Gastroenterology</i> , <b>2021</b> , 160, 1901-1902	13.3	8
48	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 687-694	1.5	7
47	Can COVID-19 Trigger De Novo Inflammatory Bowel Disease?. <i>Gastroenterology</i> , <b>2021</b> , 160, 1029-1030	13.3	7
46	Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 1297-1304	3.5	6
45	A recombined haplotype in the major histocompatibility region contains a cluster of genes conferring high susceptibility to ulcerative colitis in the Spanish population. <i>Inflammatory Bowel Diseases</i> , <b>2005</b> , 11, 785-91	4.5	6
44	Simultaneous two-level esophageal 24-hour pH monitoring in patients with mild and severe esophagitis. Does probe position influence results of esophageal monitoring?. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 1423-7	4	5
43	Recurrent granulomatous cheilitis associated with Crohn's disease successfully treated with ustekinumab: case report and literature review. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 1756284820934327	4.7	5
42	Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 870-879	6.1	4
41	Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 1290-1298	1.5	4
40	Polymorphisms in interleukin-10 gene according to mutations of NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 443-8	5.6	4
39	Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 571-572	6.1	3



38	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal. <i>Enfermedad Inflamatoria Intestinal Al Día</i> , <b>2015</b> , 14, 109-119		3
37	Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: a comparative analysis of nine scoring methods. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 51-9	2.4	3
36	Differences in the need for adalimumab dose optimization between Crohn's disease and ulcerative colitis. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2019</b> , 111, 846-851	0.9	3
35	Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. <i>Scientific Reports</i> , <b>2020</b> , 10, 17774	4.9	3
34	Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicron study. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 807-813	4.2	2
33	Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 529-535	3.3	2
32	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 588-596	2.2	2
31	Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient. <i>Actas Dermo-sifiliográficas</i> , <b>2018</b> , 109, 584-601	0.5	2
30	Letter: Recommendations for the management of latent tuberculosis infection in IBD patients may not be applicable in all settings. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 365-6	6.1	2
29	Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease. <i>Journal of Crohns and Colitis</i> , <b>2012</b> , 6, 488-91	1.5	2
28	Analysis of a non-synonymous single nucleotide polymorphism of the human diamine oxidase gene (ref. SNP ID: rs1049793) in patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2009</b> , 44, 1207-12	2.4	2
27	Letter: SARS-CoV-2 induced gastrointestinal inflammation-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1750-1751	6.1	2
26	P424 Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S321-S322	1.5	1
25	Letter: immunotherapy for IBD patients in a SARS-CoV-2 endemic area-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 900-901	6.1	1
24	OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S026-S028	1.5	1
23	Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: results from the PRACTICROHN study. <i>Gastroenterology Report</i> , <b>2019</b> , 7, 411-418	3.3	1
22	Polymorphisms in the interleukin-10 gene and relation to phenotype in patients with ulcerative colitis. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2006</b> , 98, 93-100	0.9	1
21	Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2017</b> , 109, 690-693	0.9	1

20	Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 583-98	4.5	1
19	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , <b>2021</b> , 44, 51-66	0.9	1
18	Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 1-11	2.2	1
17	Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	1
16	Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00218	4.2	0
15	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819874202	4.7	0
14	Impact of the recommendations made by Spanish Club for the Study of Helicobacter pylori on eradication indications. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2002</b> , 94, 332-9	0.9	0
13	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819867848	4.7	
12	DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S052-S053	1.5	
11	P443 Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study). <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S332-S333	1.5	
10	P559 Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S393-S394	1.5	
9	P223 Efficacy and safety of tacrolimus in Crohn's disease: a nationwide, multi-centric study from GETECCU. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S207-S208	1.5	
8	DOP063 Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, S63-S63	1.5	
7	P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S328-S329	1.5	
6	Topical anesthesia and urease tests. <i>Gastrointestinal Endoscopy</i> , <b>1996</b> , 44, 760	5.2	
5	Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211056157	4.7	
4	P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S489-S490	1.5	
3	ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2021</b> , 113, 737-738	0.9	



- 2 Recommendations for the detection of latent tuberculosis infection in patients with immune-mediated inflammatory diseases candidates for anti-TNF therapy may not be applicable in all settings. *Rheumatology International*, **2021**, 1 3.6
- 1 Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 1249-1250 6.1